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Background: Head and neck squamous cell carcinoma (HNSCC) is a type of cancer that is 
strongly associated with oxidative damage and oxidative stress. Tobacco and alcohol – sources 
of massive quantities of reactive oxygen species (ROS) – have been clearly identified as etiologic 
factors that contribute to these malignancies. Considering the role of glutathione (GSH) in ROS 
detoxification, we hypothesized that potential biological markers can be found in addition to the 
parameters of oxidative stress. In line with previous studies that emphasized the accumulation 
of GSH in tumor cells, in this study, we have reported a lower ratio of oxidized versus reduced 
GSH in head and neck tumors.
Objective: The aim of the paper was to evaluate the prognostic and clinical significance of the 
ratio of oxidized versus reduced GSH in patients with head and neck cancers.
Methods: Thirty-six patients with HNSCC were included in this study. The tumoral redox status 
was determined by measuring the ratio of oxidized/reduced GSH (GSSG/GSH) by capillary 
electrophoresis. Statistical analysis was performed to assess the correlation between patient, 
clinical factors and the redox status.
Results: The results showed a low tumoral ratio of GSSG/GSH and a better locoregional control. 
Moreover, a significant correlation between the tumoral redox status ratio (GSSG/GSH) and 
nodal stage (N0 versus N1, N2 and N3) was also observed. A higher tumoral redox status ratio 
was found to be associated with the presence of lymph node metastasis (N1, N2 and N3).
Conclusion: A strong correlation was observed between the oxidative status and locoregional 
control of the tumors. Moreover, a higher basal tumoral redox status ratio was found to be cor-
related with the presence of lymph node metastasis.
Keywords: oxidative stress, head and neck cancer, glutathione ratio, prognostic factor, lymph 
node metastasis
Introduction
Recently, oxidative stress alterations have been well established as a hallmark of cancer. 
This factor is of particular importance in causing tumors of the head and neck, as these 
are strongly associated with oxidative damage and oxidative stress, with tobacco and 
alcohol clearly defined as major etiologic factors. Increased levels of reactive oxygen 
species (ROS) are commonly found in cancer cells, and cancer cells of other types 
also demonstrate increased sensitivity to ROS.
Cancer cells and normal cells adapt to oxidative stress by activation of multiple 
pathways including kinase signal transduction pathways and transcription factors, 
which results, among other effects, in the upregulation of genes that encode antioxidant 
enzymes and molecules.1
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Among these, glutathione (GSH) is an important 
antioxidant because several of the antioxidant mechanisms 
that involve reduction reactions ultimately rely on the oxi-
doreduction of GSH.1,2
Low levels of intracellular GSH decrease cellular anti-
oxidant capacity, whereas elevated levels of GSH generally 
increase the antioxidant capacity and resistance to oxida-
tive stress. This phenomenon is observed in many types of 
cancer cells.2,3 In this study, we investigated the clinical and 
prognostic significance of the ratio of oxidized/reduced GSH 
(GSSG/GSH) in cancer tissues in a cohort of 36 head and 
neck cancer patients.
Materials and methods
The present study was approved by the Ethic Committee 
of André Vésale Hospital (OM008) under CCB num-
ber B32520107991. After obtaining approval from the 
committee and written informed consent of all the patients, 
36 newly diagnosed head and neck squamous cell carcinoma 
(HNSCC) patients were prospectively included in this study. 
There were 6 females and 30 males and the median age 
was 59 years. The numbers of patients with tumor-node-
metastasis (TNM) stages I, II, III and IV were 4, 5, 3 and 
24, respectively. Patients were categorized based on tumor 
localization: 15 patients with tumor in larynx, 9 patients with 
tumor in pharynx, 8 with tumor in hypopharynx and 4 in 
oropharynx (Table 1). All patients were treated surgically. 
Radiotherapy was initiated in 10 patients 4–6 weeks after 
surgery. All these patients received between 50 and 70 Gy 
of radiation; they were treated once a day with conventional 
fractionation, 5 times a week, over the course of 6 weeks. 
Seventeen of the 36 patients received concomitant chemo-
radiotherapy. Median follow-up was 63 months.
First, the surgical specimen was analyzed by an anato-
mopathologist to differentiate between the normal (without 
any presence of cancer cells) and tumor tissues. The same 
procedure was followed for heterogeneous tumors to exclude 
necrosis and to select tumoral specimen with cancerous cells 
by microscopy. Second, the ratio of oxidized to reduced GSH 
was determined using the capillary electrophoresis kit, Ceofix 
(Analis, Namur, Belgium), according to the manufacturer’s 
instructions and as per the data available in the literature.1,2 
Briefly, 200 μL of whole blood and healthy and tumor tissues 
were obtained from the patient, immediately ground with 
600 μL of 5% metaphosphoric acid and centrifuged (within 
3 hours). A total of 100 mL of the supernatant was mixed with 
400 μL of the kit diluent, containing naphthalene sulfonic 
acid as internal standard. The sample was analyzed using a P/
ACE 5000 series with 37 cm and 75 μm identified by capillary 
maintained at 25°C. Separation of the contents was performed 
at 8 kV with borate buffer at pH 8.2 containing SDS. The 
peaks of oxidized and reduced GSH were detected at 200 nm 
and integrated. The total integrated area of the oxidized GSH 
peak was then divided by that of the reduced one.
Cox proportional hazard analysis was performed to 
assess the relation between redox status (oxidized/reduced 
glutathione [GSSG/GSH]) of the untreated tumor biopsies 
and clinical end points such as locoregional control (LRC), 
overall survival (OS) and disease-specific survival (DSS). 
OS was defined as the time between the start of treatment 
and death; DSS as the time between the start of treatment 
and disease-specific recurrence or death; and LRC as the 
time between the start of treatment and date of locoregional 
recurrence. Correlation between clinical/patient characteris-
tics and redox status was assessed using ANOVA. The redox 
status was defined as the ratio of GSSG and GSH and was 
assessed as a continuous variable. The following conditions 
were assessed as a binary variable: nodal stage – absence of 
nodal involvement (N0) and presence of nodal involvement 
(N1, N2 and N3); T-stage – lower T-stages (T1 and T2) and 
higher T-stages (T3 and T4); and disease stage – lower dis-
ease stages (I and II) and higher disease stages (III and IV) 
Table 1 characteristics of 36 patients
Parameters Number of 
patients 
gender
Male 30
Female 6
age, years
Median (range) 59 (47–81)
nodal stage
n0 20
n1/n2/n3 16
T-stage
T1/T2 14
T3/T4 22
Disease stage
i–ii 9
iii–iV 27
Tumor site
hypopharynx 8
Oropharynx 4
Pharynx 9
larynx 15
Treatment
rT 10
rT + cT 17
no adjuvant treatment 9
redox potential
Mean gssg/gsh tumor (range) 6.69 (0.88–46.6)
Abbreviations: rT, radiotherapy; rT + cT, concomitant chemoradiotherapy; 
gssg/gsh, oxidized/reduced glutathione.
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(Table S1). All analyses were 2-sided and performed using 
Statistica software (version 12). P-values #5% were consid-
ered significant for all tests.
Results
Histological examination of the surgical specimens showed 
the presence of squamous cell carcinomas in all cases: 
poorly differentiated in 4 cases (11%), moderately dif-
ferentiated in 14 cases (39%) and well differentiated in 18 
cases (50%).
The results were expressed as delta values, that is, the 
difference between the normal mucosa and tumor tissues – 
which highlights the variability among the samples. The 
results obtained showed that 21 patients had a lower 
tumoral ratio of GSSG/GSH compared with normal tissues 
(58.3%), whereas 15 patients (41.7%) had a higher tumoral 
GSSG/GSH ratio.3
Oxidative stress ratio obtained by Cox regression analysis 
showed no significant difference in the OS. A strong correla-
tion was observed between the LRC rates of the tumors and 
their oxidative status (hazard ratio =0.69) (confidence inter-
val [CI]: 0.44–1.08; P=0.1). Moreover, univariate analyses 
showed a significant association between the tumoral redox 
status ratio (GSSG/GSH) and nodal stage (N0 versus N1, 
N2 and N3), with a higher tumoral redox status ratio associated 
with the presence of lymph node metastasis (N1, N2 and N3) 
(Figure 1). No significant correlation was observed between 
tumoral GSSG/GSH and disease stage and T-stage.
Discussion
Head and neck cancer cells adapt to oxidative stress by acti-
vation of multiple pathways. Among the different salvage 
pathways, GSH plays a key role in ROS detoxification. 
GSH is found in two forms: free or bound to proteins. The 
free form is present mainly in its reduced form (GSH), 
which is converted to its oxidized form (GSSG) during 
oxidative stress.4
Oxidative damage is prevented by the reduction of GSSG 
to GSH in the presence of GSSG reductase at the expense of 
NADPH, which results in a redox cycle. Organic peroxides 
can be reduced both by glutathione peroxidase X and GSH-
transferase (GST). In extreme oxidative stress conditions, 
the ability of the cell to reduce GSSG to GSH is decreased, 
thereby resulting in the accumulation of GSSG within the 
cytosol. To avoid a shift in the redox equilibrium, the GSSG 
is actively transported out of the cell or it is reacted with 
protein sulfhydryl groups.
Therefore, in this study, we focused on the ratio of GSSG/
GSH because the antioxidant cellular armada involves cas-
cades of oxidoreduction, which ultimately result in oxidized/
reduced GSH. Furthermore, the equilibrium of this reaction 
depends on the concentrations of GSH and GSSG, and their 
molar ratios are indicators of cell functionality and oxida-
tive stress.4
However, we have previously demonstrated a large 
variability in the tumoral concentrations of GSH and GSSG 
which is in agreement with the results reported in the litera-
ture (from 0.69±0.73 μmol/g tissue to 30.14±6.37 mg/mg 
protein).3 Moreover, we observed that a considerable pro-
portion (58.3%) of tumor patients exhibited a lower ratio of 
GSSG/GSH compared to healthy individuals. These results, 
also observed for tumors of other types, are consistent with 
those found in the literature.4,5
It is also well known that any change in the intracellular 
GSSG/GSH ratio results in the activation of cell proliferation 
and cell death. Little is known, however, about the clinical 
and the prognostic significance of the ratio GSSG/GSH in 
tumor tissues.
In this study, we have investigated the prognostic sig-
nificance of the tumoral ratio of GSSG/GSH by assessing 
the correlation between oxidized/reduced GSH in tumoral 
tissue and clinical parameters of head and neck cancer 
patients.
Few studies have evaluated the correlation between clini-
copathological parameters and GSH. Two studies found 
no correlation between GSH levels and the degree of 
differentiation.6,7 However, Wong et al found higher levels 
of GSH in well differentiated oral carcinoma compared 
with moderately differentiated tumors.8 Kolanjiappan et al 
and Parise et al reported increasing GSH levels with tumor 
stage.9,10 This correlation was not found by Guichard et al6 
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Figure 1 Box plot showing the mean values of the ratio of oxidized and reduced 
glutathione (GSSG/GSH) (with 95% confidence interval) for nodal stages indicated 
(n0 versus n1/n2/n3), P=0.05.
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but they limited their study to primarily T2 and T3 patients.11 
Similarly, Inci et al found no difference in GSH levels when 
comparing patients grouped as either stage I/II or stage III.12 
Likewise, Wong et al found no correlation between GSH 
levels and the tumor size in oral carcinoma and Lafuente 
et al found no correlation in laryngeal tumors.8,13 In addition, 
some authors reported that GSH level increased with tumor 
size, mainly with the nodal status.14
In this study, we observed a strong correlation between 
the levels of oxidized and reduced GSH in tumor tissues 
and the nodal status of the head and neck cancer patients. 
A lower GSSG/GSH ratio was observed in tumor tissues of 
N0 patients, while a higher GSSG/GSH ratio was observed 
in positive node patients. This suggests that tumors with a 
higher GSSG/GSH ratio might have a tendency to spread 
more locally, due to their more aggressive phenotype caused 
by oxidative stress. However, the exact role of GSH in the 
prognosis of HNSCC is not fully understood. Previous studies 
have indicated that HNSCC patients with a lower GSH level 
may be highly sensitive to antitumor treatments, which may 
result in a better outcome, whereas increased GSH levels are 
associated with drug resistance and poor prognosis.1,15
To date, no studies have evaluated the relationship 
between patient outcome and GSH measurements.8 The most 
promising result of our study is that patients with a lower 
GSSG/GSH ratio compared to those with higher ratio had 
a lower risk of local and regional recurrence of tumor after 
treatment. This suggests a more aggressive behavior of the 
tumors with high oxidative stress.
Limitations
Our study has few limitations. The sample size included in 
our study is small, which is a common problem to many 
studies related to head and neck tumors, and is due to their 
heterogeneity. Another limitation is the lack of multivari-
ate analysis, due to the relatively small number of patients 
included.
Conclusion
Despite these limitations, we confirmed a correlation between 
higher tumoral ratio of GSSG/GSH and the initial spread 
of nodal metastasis. This result shows that a lower tumoral 
GSSG/GSH ratio at the time of the initial treatment has a 
higher tendency for LRC. This observation suggests that 
pretherapeutic tumoral ratio of GSSG/GSH is of prognos-
tic value. However, a prospective study with large patient 
population should be carried out to further validate these 
findings.
Disclosure
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Supplementary material
Table S1 Distribution of patients according to nodal stage
N-stage N0 N1/N2/N3 Total
number of patients (n) 20 16 36
age, years
Mean 61.8 57.8
gender
Male 18 12 30
Female 2 4 6
localization
larynx 10 5 15
hypopharynx 2 6 8
Pharynx 4 5 9
Oropharynx 4 0 4
T-stage
T1/T2 10 4 14
T3/T4 10 12 22
Disease stage
l–ll 10 4 14
lll–iV 10 12 22
Tumor site
larynx 10 5 15
hypopharynx 2 6 8
Pharynx 4 5 9
Oropharynx 4 0 4
redox potential
Mean gssg/gsh tumor 4.3 9.5 6.6
Abbreviation: gssg/gsh, oxidized and reduced glutathione.
